Procalcitonin values after dialysis is closely related to type of dialysis membrane

References

• Khan IN, Catto GRD. Long-term complications of dialysis: infection. Kidney Int. 1993; 43:143–8.
   Google Scholar
• Katneni R, Hedayati SS. Central venous catheter-related bacteremia in chronic hemodialysis patients: epidemiology and evidence-based management. Nat Clin Pract Nephrol. 2007; 3:256–66.
   PubMedGoogle Scholar
• Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial. 2007; 20:440–51.
   PubMed Web of Science ®Google Scholar
• Rangel MC, Coronado VG, Euler GL, Strikas RA. Vaccine recommendations for patients on chronic dialysis. Semin Dial. 2000; 13:101–7.
   PubMedGoogle Scholar
• Herget-Rosenthal S, Marggraf G, Pietruck F, Hüsing J, Strupat M, Philipp T, Kribben A. Procalcitonin for accurate detection of infection in haemodialysis. Nephrol Dial Transplant. 2001; 16:975–9.
   PubMed Web of Science ®Google Scholar
• Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis. Kidney Int. 1999; 55:648–58.
   PubMed Web of Science ®Google Scholar
• Haverkate F, Thompson SG, Pype SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997; 349:462–6.
   PubMed Web of Science ®Google Scholar
• Schneider HG, Lam QT. Procalcitonin for the clinical laboratory: a review. Pathology. 2007; 39:383–90.
   PubMed Web of Science ®Google Scholar
• Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004; 39:206–17.
   PubMed Web of Science ®Google Scholar
• Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, Bohuon C. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994; 79:1605–8.
   PubMed Web of Science ®Google Scholar
• Nylen ES, Whang KT, Snider RH, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med. 1998; 26:1001–6.
   PubMed Web of Science ®Google Scholar
• Herbelin A, Nguyen AT, Zingraff J, Urena P, Deschamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor. Kidney Int. 1990; 37:116–25.
   PubMed Web of Science ®Google Scholar
• Herbelin A, Urena P, Nguyen AT, Zingraff J, Deschamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int. 1991; 39:954–60.
   PubMed Web of Science ®Google Scholar
• Maruna P, Nedelnikova K, Gürlich R. Physiology and genetics of procalcitonin. Physiol Res. 2000; 49:S57–61.
   PubMed Web of Science ®Google Scholar
• Carrol ED, Thomson AP, Hart CA. Procalcitonin as a marker of sepsis. Int J Antimicrob Agents. 2002; 20:1–9.
   PubMed Web of Science ®Google Scholar
• Meisner M, Tschaikowsky K, Palmaers T, Schmidt J. Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care. 1999; 3:45–50.
   PubMed Web of Science ®Google Scholar
• Boeken U, Feindt P, Micek M, Petzold T, Schulte HD, Gams E. Procalcitonin in cardiac surgery: diagnostic value in systemic inflammatory response syndrome (SIRS), sepsis and after heart transplantation. Cardiovasc Surg. 2000; 8:550–4.
   PubMedGoogle Scholar
• Schüttrumpf S, Binder L, Hagemann T, Berkovic D, Trümper L, Binder C. Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients?. Ann Hematol. 2003; 82:98–103.
   PubMed Web of Science ®Google Scholar
• Panichi V, Rizza GM, Paoletti S, Bigazzi R, Aloisi M, Barsotti G, Rindi P, Donati G, Antonelli A, Panicucci E, Tripepi G, Tetta C, Palla R. RISCAVID Study Group. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant. 2008; 23:2337–43.
   PubMed Web of Science ®Google Scholar
• Kim BS, Jeon DS, Shin MJ, Kim YO, Song HC, Lee SH, Kim SY, Choi EJ, Chang YS, Bang BK. Persistent elevation of C-reactive protein may predict cardiac hypertrophy and dysfunction in patients maintained on hemodialysis. Am J Nephrol. 2005; 25:189–95.
   PubMed Web of Science ®Google Scholar
• Hengst JM. The role of C-reactive protein in the evaluation and management of infants with suspected sepsis. Adv Neonatal Care. 2003; 3:3–13.
   PubMedGoogle Scholar
• Ugarte H, Silva E, Mercan D, De Mendonca A, Vincent JL. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med. 1999; 27:498–504.
   PubMed Web of Science ®Google Scholar
• Peres Bota D, Melot C, Lopes Ferreira F, Vincent JL. Infection Probability Score (IPS): a method to help assess the probability of infection in critically ill patients. Crit Care Med. 2003; 31:2579–84.
   PubMed Web of Science ®Google Scholar
• Povoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, Sabino H. C-reactive protein as a marker of ventilator-associated pneumonia resolution – a pilot study. Eur Respir J. 2005; 25:804–12.
   PubMed Web of Science ®Google Scholar
• Prat C, Sancho JM, Dominguez J, Xicoy B, Gimenez M, Ferra C, Blanco S, Lacoma A, Ribera JM, Ausina V. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma. 2008; 49:1752–61.
   PubMed Web of Science ®Google Scholar
• Conti G, Amore A, Chiesa M, Mancuso D, Cirina P, Mengozzi G, Santoro A, Coppo R. Procalcitonin as a marker of micro-inflammation in hemodialysis. J Nephrol. 2005; 18:282–8.
   PubMedGoogle Scholar
• Rinaldi S, Adembri C, Grechi S, De Gaudio AR. Low-dose hydrocortisone during severe sepsis: effects on microalbuminuria. Crit Care Med. 2006; 34:2334–9.
   PubMedGoogle Scholar
• Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008; 177:498–505.
   PubMed Web of Science ®Google Scholar
• Vanholder R, Schepers E, Meert N, Lameire N. What is uremia? Retention vs oxidation. Blood Purif. 2006; 24:33–8.
   PubMed Web of Science ®Google Scholar
• Galli F. Protein damage and inflammation in uraemia and dialysis patients. Nephrol Dial Transplant. 2007; 22Suppl. 5:v20–36.
   PubMed Web of Science ®Google Scholar
• Ooi DS, House AA. Cardiac troponin T in hemodialyzed patients. Clin Chem. 1998; 44:1410–6.
   PubMed Web of Science ®Google Scholar